Market Research Logo

Pyelonephritis - Pipeline Review, H1 2018

Pyelonephritis - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pyelonephritis - Pipeline Review, H1 2018, provides an overview of the Pyelonephritis (Infectious Disease) pipeline landscape.

Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in urethra or bladder and travels up into kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion and back pain or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract and damage to nerves around the bladder. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pyelonephritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pyelonephritis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 4, 1 and 1 respectively.

Pyelonephritis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pyelonephritis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pyelonephritis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pyelonephritis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pyelonephritis (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pyelonephritis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Pyelonephritis - Overview
Pyelonephritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pyelonephritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pyelonephritis - Companies Involved in Therapeutics Development
Achaogen Inc
AstraZeneca Plc
Entasis Therapeutics Inc
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Paratek Pharmaceuticals Inc
Zavante Therapeutics Inc
Pyelonephritis - Drug Profiles
(AAI-101 + cefepime) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(avibactam + ceftazidime) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(meropenem + vaborbactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-2514 + sulbactam sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfomycin tromethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nacubactam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omadacycline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plazomicin sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulopenem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pyelonephritis - Dormant Projects
Pyelonephritis - Discontinued Products
Pyelonephritis - Product Development Milestones
Featured News & Press Releases
Feb 27, 2018: Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE (meropenem and vaborbactam) in Patients with cUTI
Jan 30, 2018: Achaogen Announces Upgraded Status for Plazomicin Fill Manufacturer
Oct 26, 2017: Achaogen Submits Plazomicin New Drug Application (NDA) to the U.S. FDA for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections
Oct 05, 2017: The Medicines Company to Present New Data from TANGO II Study of VABOMERE™ (meropenem and vaborbactam) at IDWeek 2017
Oct 05, 2017: Achaogen IDWeek 2017 Presentations Feature Plazomicin’s Unique Potential to Treat MDR Enterobacteriaceae
Oct 04, 2017: Merck Highlights Data on ZERBAXA at ID Week 2017
Sep 27, 2017: Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017
Aug 30, 2017: The Medicines Company Announces FDA Approval of VABOMERE (meropenem and vaborbactam)
Jun 05, 2017: Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting
Apr 17, 2017: The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam
Jan 30, 2017: FDA Approves Allergan's sNDA for AVYCAZ (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections, Including Pyelonephritis
Oct 26, 2016: Merck Highlights Data Presentation on ZERBAXA at ID Week 2016
Oct 11, 2016: FDA Accepts Supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam)
Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
Jun 15, 2016: Merck Presents Data on ZERBAXA (ceftolozane and tazobactam) at ASM Microbe 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pyelonephritis, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pyelonephritis - Pipeline by Achaogen Inc, H1 2018
Pyelonephritis - Pipeline by AstraZeneca Plc, H1 2018
Pyelonephritis - Pipeline by Entasis Therapeutics Inc, H1 2018
Pyelonephritis - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018
Pyelonephritis - Pipeline by Melinta Therapeutics Inc, H1 2018
Pyelonephritis - Pipeline by Merck & Co Inc, H1 2018
Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2018
Pyelonephritis - Pipeline by Paratek Pharmaceuticals Inc, H1 2018
Pyelonephritis - Pipeline by Zavante Therapeutics Inc, H1 2018
Pyelonephritis - Dormant Projects, H1 2018
Pyelonephritis - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Pyelonephritis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report